Clinical Trials
28 trialsGBM AGILE
Global Coalition for Adaptive Research
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies, LLC
ARISTOCRAT
University of Birmingham
PEEL-224
Children's Hospital of Philadelphia
PRiME II
Washington University School of Medicine
Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
MEMMAT
Medical University of Vienna
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
National Institutes of Health Clinical Center (CC)
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Australian & New Zealand Children's Haematology/Oncology Group
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Novartis
Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)
Duke University
RESIST
Duke University
A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse
Beijing Sanbo Brain Hospital
Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Henry Ford Health System
RE-GEND
Kyorin University
Metformin in Children With Relapsed or Refractory Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Provectus Pharmaceuticals
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU Langone Health
Toca5
Tocagen Inc.
DRBEAT
Cedars-Sinai Medical Center
HIT-REZ-2005
University Hospital, Bonn
D24GBM
Clinica Universidad de Navarra, Universidad de Navarra
Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma
Burzynski Research Institute
Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
Ohio State University Comprehensive Cancer Center
SEED
Seattle Children's Hospital
HGG-CilMetro
Martin-Luther-Universität Halle-Wittenberg
To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors
Abbott
Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma
University of Zurich